Apogee Therapeutics

Apogee Therapeutics develops biologic therapies for atopic dermatitis. Its lead antibody targets IL-13 and offers convenient quarterly dosing.
Domain
Healthcare
Status
IPO’d/​Acquired
IPO Date
2023
Stage of Initial Investment
Series B
Initial Investment Year
2022
Apogee Portco Hover Image2